ClinicalTrials.gg
WithdrawnNCT03710044Updated Nov 7, 2024

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

A Phase 4 interventional study of Cyclosporine A in Atopic Dermatitis, sponsored by LEO Pharma. Withdrawn at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by LEO Pharma · Phase 4, Interventional, and Other

Why this study was withdrawn
Strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing cyclosporine in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. Cyclosporine · Dermatitis, Atopic.

Started
2019
the only one that year
Phase 4
4 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
LEO Pharma

Among the 11 studies testing cyclosporine in Dermatitis, Atopic, this one is the only one that started in 2019, is one of 4 in phase 4, and was the 8th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing cyclosporine in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cyclosporine in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The trial is an exploratory, single-centre, uncontrolled, open-label, interventional trial of up to 19 weeks' duration to investigate flare and remission in subjects with moderate-to-severe atopic dermatitis (AD) treated with cyclosporine A (CsA).

Read the detailed description

40 subjects with moderate-to-severe AD will be treated with a 3-week course of high-dose CsA, which is a standard-of-care treatment regimen. After 3 weeks, all responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).

In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • atopic dermatitis
  • cyclosporine A
  • atopic dermatitis pathophysiology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Diagnosis and history of chronic, moderate-to-severe AD (by the Eichenfield revised criteria of Hanifin and Rajka) for at least 3 years before the screening visit.
  • Subjects who have an AD flare at the start of the trial (EASI score ≥10 at screening and ≥16 at the baseline visit).

Main Exclusion Criteria:

  • Treatment with allergen immunotherapy within 6 months before the baseline visit.
  • Treatment with leukotriene inhibitors, systemic , or other systemic treatment for AD (including treatment, ultraviolet therapy, and biologics) within 4 weeks before the baseline visit.
  • Treatment with topical corticosteroids or topical calcineurin inhibitors within 1 week before the baseline visit.
  • Chronic or acute infection requiring treatment with oral or intravenous antibiotics, anti-virals, anti-parasitics, anti-protozoals, or anti-fungals within 4 weeks before the screening visit or superficial skin infections within 1 week before the screening visit.
  • History of within 5 years before the baseline visit, with the following exceptions: subjects with a history of completely treated carcinoma in situ of cervix, and non- squamous or basal cell carcinoma of the skin are allowed.
  • Hypertension (>150/95 mmHg) at the screening visit.
  • Planned surgical procedure during the length of the subject's participation in this trial.
  • Use of a tanning booth/parlour within 4 weeks before the screening visit.
  • Pregnant, breastfeeding, or lactating women.
  • Laboratory abnormalities at the screening visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cyclosporine A treatment

    Oral cyclosporine A treatment

    Drug: Cyclosporine A

Interventions

  • Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks. Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113). In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.

06

What researchers measure

Primary outcomes

  1. Time to flare* in subjects with moderate-to-severe AD who responded to a 3-week course of high-dose CsA treatment.

    \*A flare is defined as exacerbation of the disease, where intensification of medicine is considered necessary.

    Time frame: Day 1 to Day 113 (end of trial)

Secondary outcomes

  1. Number of treatment-emergent adverse events (TEAEs) up until end of trial.

    Time frame: Up to Day 113 (end of trial)

  2. Number of subjects with TEAEs up until end of trial.

    Time frame: Up to Day 113 (end of trial)

07

Study locations

1 site
  • Investigational site
    Rotterdam, 3015 GD, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for Aug 2020, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2018
First posted
Oct 17, 2018
StartActual
Jan 14, 2019
Primary completionEst.
Aug 2020
CompletionEst.
Aug 2020
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03710044
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Jan 14, 2019
Primary completion
Aug 2020 (estimated)
Completion
Aug 2020 (estimated)
Last update
Nov 7, 2024

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion